Article ID Journal Published Year Pages File Type
4133947 Human Pathology 2010 8 Pages PDF
Abstract

SummaryBreast cancer cells with the CD44+/CD24− phenotype have been associated with stem cell properties. To analyze effects of cytotoxic chemotherapy on these cells, we examined a series of 50 breast carcinomas before and after neoadjuvant chemotherapy with epirubicin/cyclophosphamide using double immunofluorescence. Before treatment, an average of 4.4% of the tumor cells displayed a CD44+/CD24− phenotype. However, after chemotherapy, the frequency of CD44+/CD24− cells dropped to 2% (P = .008). To test this unexpected finding, we analyzed a second collective of 16 patients that preoperatively had received either 4 cycles of doxorubicin/pemetrexed, followed by 4 cycles of docetaxel or 4 cycles of doxorubicin/cyclophosphamide, followed by 4 cycles of docetaxel with similar results (8.7% CD44+/CD24− cells on average before and 1.1% after chemotherapy). In addition, no association was observed between the frequency of CD44+/CD24− cells and the response to chemotherapy or patient survival. However, patients with tumors containing high numbers of CD44+/CD24− cells more frequently developed bone metastases in the course of disease. In conclusion, our findings challenge the proposed role of CD44+/CD24− cells as cancer stem cells in tumor resistance to chemotherapy as they apparently are not selected by conventional cytotoxic agents.

Related Topics
Health Sciences Medicine and Dentistry Pathology and Medical Technology
Authors
, , , , , ,